"Immunotherapy, Active" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
| Descriptor ID |
D016233
|
| MeSH Number(s) |
E02.095.465.425.400.530 E05.478.550.600
|
| Concept/Terms |
Immunotherapy, Active- Immunotherapy, Active
- Active Immunotherapy
- Active Immunotherapies
- Immunotherapies, Active
Vaccine Therapy- Vaccine Therapy
- Therapy, Vaccine
- Therapies, Vaccine
- Vaccine Therapies
Immune RNA Manipulation- Immune RNA Manipulation
- Immune RNA Manipulations
- Manipulation, Immune RNA
- Manipulations, Immune RNA
- RNA Manipulation, Immune
- RNA Manipulations, Immune
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Active".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Active".
This graph shows the total number of publications written about "Immunotherapy, Active" by people in this website by year, and whether "Immunotherapy, Active" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Active" by people in Profiles.
-
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017 04 07; 10(1):82.
-
A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin Colorectal Cancer. 2006 Jan; 5(5):368-71.